Results 41 to 50 of about 196,164 (338)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis

Arthritis & Rheumatology, 2020
To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of refractory lupus nephritis (LN).
Y. Atisha-Fregoso, S. Malkiel, Kristina M. Harris, M. Byron, L. Ding, S. Kanaparthi, William T. Barry, Wendy Gao, Kristin Ryker, Patti Tosta, A. Askanase, S. Boackle, W. Chatham, D. Kamen, David Karp, K. Kirou, S. Sam Lim, B. Marder, M. McMahon, Samir V. Parikh, W. Pendergraft, Amber S. Podoll, A. Saxena, D. Wofsy, B. Diamond, Dawn Smilek, C. Aranow, M. Dall'era   +27 more
semanticscholar   +1 more source

Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

Journal of Immunology Research, 2014
We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy.
Heiner Zimmermann, Theresa Weiland, Jamie P. Nourse, Maher K. Gandhi, Petra Reinke, Ruth Neuhaus, Mohsen Karbasiyan, Barbara Gärtner, Ioannis Anagnostopoulos, Hanno Riess, Ralf U. Trappe, Stephan Oertel   +11 more
doaj   +1 more source

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.

Neurology, 2021
OBJECTIVE To determine whether rituximab is safe and potentially beneficial, warranting further investigation in an efficacy trial for acetylcholine receptor antibody-positive generalized MG (AChR-Ab+ gMG).
R. Nowak, C. Coffey, J. Goldstein, M. Dimachkie, M. Benatar, J. Kissel, G. Wolfe, T. Burns, M. Freimer, S. Nations, V. Granit, A. Smith, D. Richman, E. Ciafaloni, M. Al-Lozi, Laura Sams, D. Quan, E. Ubogu, Brenda L. Pearson, Aditi Sharma, Jon W. Yankey, L. Uribe, M. Shy, A. Amato, R. Conwit, K. O’Connor, D. Hafler, M. Cudkowicz, R. Barohn   +28 more
semanticscholar   +1 more source

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey

Pharmaceuticals, 2014
Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources.
William H. Baer II, Archana Maini, Ira Jacobs   +2 more
doaj   +1 more source

Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. [PDF]

PLoS ONE, 2017
Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of 89Zirconium (89Zr)-mAb is a potential imaging biomarker
Yvonne W S Jauw, Josée M Zijlstra, Daphne de Jong, Danielle J Vugts, Sonja Zweegman, Otto S Hoekstra, Guus A M S van Dongen, Marc C Huisman   +7 more
doaj   +1 more source

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis

Cancer Medicine, 2020
Background The aim of the study was to evaluate the cost‐effectiveness of lenalidomide plus rituximab vs rituximab alone in patients with relapsed or refractory indolent lymphoma.
Peng‐Fei Zhang, Dan Xie, Feng Wen, Qiu Li   +3 more
doaj   +1 more source

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

Journal of Clinical Oncology, 2019
PURPOSE Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered.
J. Leonard, M. Trněný, K. Izutsu, N. Fowler, X. Hong, Jun Zhu, Huilai Zhang, F. Offner, A. Scheliga, G. Nowakowski, A. Pinto, F. Re, L. Fogliatto, P. Scheinberg, I. Flinn, C. Moreira, J. Cabeçadas, David R. Liu, S. Kalambakas, P. Fustier, Chengqing Wu, J. Gribben   +21 more
semanticscholar   +1 more source

Hypokalemia after rituximab administration in nephrotic syndrome: two case reports

BMC Nephrology, 2023
Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse ...
Yiyun Song, Lin Ding, Xin An, Yi Zhao, Xianhua Li, Xiangdong Yang, Xiaoyan Xiao   +6 more
doaj   +1 more source

Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20

PLoS Medicine, 2008
Background Rituximab is used in the treatment of CD20+ B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis ...
M. Winiarska, Jacek Bil, Ewa Wilczek, Grzegorz M. Wilczynski, Małgorzata Lekka, P. Engelberts, W. J. Mackus, Elzbieta Gorska, Lukasz Bojarski, Tomasz Stokłosa, D. Nowis, Zuzanna Kurzaj, Marcin Makowski, Eliza Głodkowska, Tadeusz Issat, P. Mrówka, W. Lasek, Anna Dąbrowska-Iwanicka, Grzegorz W. Basak, Maria Wasik, Krzysztof Warzocha, M. Siński, Zbigniew Gaciong, M. Jakóbisiak, P. Parren, J. Gołąb   +25 more
semanticscholar   +1 more source

Kinetics of Rituximab Excretion into Urine and Peritoneal Fluid in Two Patients with Nephrotic Syndrome

Case Reports in Nephrology, 2017
Clinical observations suggest that treatment of Rituximab might be less effective in patients with nephrotic range proteinuria when compared to nonnephrotic patients.
Klaus Stahl, Michelle Duong, Anke Schwarz, A. D. Wagner, Hermann Haller, Mario Schiffer, Roland Jacobs   +6 more
doaj   +1 more source